Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Food and Drug Administration (FDA) has announced that UltraZx Labs is voluntarily recalling UltraZx weight loss supplements as it contained undeclared Sibutramine and phenolphthalein.
Subscribe to our email newsletter
Laboratory analysis conducted by the FDA has confirmed that UltraZx contains sibutramine and phenolphthalein.
Sibutramine is a controlled substance that was removed for safety reasons from the market in October 2010.
UltraZx poses a threat to consumers because sibutramine is known to substantially increase blood pressure and/or pulse rate in some patients and may present a significant risk for patients with a history of coronary artery disease, congestive heart failure, arrhythmias or stroke.
Phenolphthalein is a chemical that is not an active ingredient in any approved drug in the US and studies have indicated that it presents a cancer causing risk.
So far, the company has not received any reports of adverse events related to this recall.
The product is marketed as a dietary supplement for use as a weight loss aid and is packaged in bottles of thirty (30) capsules of 300mg.
The affected product includes all lots/bottles/packages and was distributed from September 2014 until February 2015.